EUCTR2005-001426-84-DE进行中（未招募）不适用
CLINICAL STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND IMMUNOGENICITY OF WILATE IN CHILDREN < 6 YEARS OF AGE WITH INHERITED VON WILLEBRAND DISEASE
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Defined inherited VWD of any type.
- •Age <6 years at study admission.
- •DDAVP treatment known or suspected to be inadequate, insufficient or contraindicated.
- •An expected minimum of 5 exposure days to WILATE within 1 year of observation.
- •HIV-1/2 negative.
- •Freely given fully informed consent has been obtained from the patient's parents (in accordance with local laws, the informed consent of both parents might be necessary).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any haematological disorder other than VWD.
- •Diagnosis of acquired VWD.
- •Any known present or past inhibitor activity against VWF or FVIII.
- •Administration of DDAVP or other blood/plasma products 5 days prior to the 1st WILATE injection
- •Administration of acetylsalicylic acid 14 days before treatment with Wilate.
- •Known history of intolerance towards plasma derived or blood products.
- •Participation in another clinical study currently or during the past four weeks.
研究者
相似试验
进行中（未招募）
不适用
CLINICAL STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND IMMUNOGENICITY OF WILATE IN CHILDREN < 6 YEARS OF AGE WITH INHERITED VON WILLEBRAND DISEASEInherited von Willebrand DiseaseMedDRA version: 8.0Level: PTClassification code 10047715EUCTR2005-001426-84-CZOctapharma AG20
进行中（未招募）
不适用
Clinical Study to Investigate the Efficacy, Safety, and Immunogenicity of human-cl rhFVIII in Previously Treated Patients With Severe Haemophilia ASevere haemophilia A (FVIII:C <1%)EUCTR2009-011055-43-ATOctapharma AG32
进行中（未招募）
不适用
The main purpose of this study is to investigate the efficacy and safety of human-cl rhFVIII during prophylaxis but also if the patient needs treatment of spontaneous or traumatic bleeding episodes, and prior to and during or after surgery.EUCTR2009-011055-43-GBOctapharma AG32
进行中（未招募）
不适用
The main purpose of this study is to investigate the efficacy and safety of human-cl rhFVIII during prophylaxis but also if the patient needs treatment of spontaneous or traumatic bleeding episodes, and prior to and during or after surgery.Severe haemophilia A (FVIII:C <=1%)MedDRA version: 13.1Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2009-011055-43-DEOctapharma AG32
已完成
不适用
A Clinical Study to Evaluate the Efficacy, Safety and Consumer Perception of a Moisturizing Productsensitive skinJPRN-UMIN000047956ION CORPORATIO35